A novel prognostic risk classification model for NUT midline carcinoma: a largest cohort analysis from the NMC registry.
Nicole G. Chau(University of British Columbia), Christopher A. French(Harvard University), Kristina Danga(Brigham and Women's Hospital), Geoffrey I. Shapiro(Brigham and Women's Hospital), Valentina Nardi(Biopredic (France)), Christopher S. Lathan(Harvard University), Robert I. Haddad(Georgetown University), Stephen E. Sallan, Clement Ma(University of Toronto), Arindam Dhar(GlaxoSmithKline (United States)), Hasan Al‐Sayegh(Sultan Qaboos University), Jeanenne J. Nelson(GlaxoSmithKline (United States)), Steven G. DuBois(University of California, San Francisco), Madhumitha Sridharan(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Ryan Barrette(Brigham and Women's Hospital)
Cited by 14
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k